Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21702748 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL25635593 | 1.00 | NR1H2 (0.42) | NR1H2HSD17B10SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL21748957 | 0.89 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL31240033 | 0.89 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL13312684 | 0.89 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL21748956 | 0.89 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL21748959 | 0.89 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL31239821 | 0.88 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL8274531 | 0.86 | SMN1; SMN2 (0.43) | NR1H2HSD17B10SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL13344518 | 0.86 | SMN1; SMN2 (0.43) | NR1H2HSD17B10SMN1; SMN2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833672-B1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-09-18 | — | — | EP | disclosed |
| CN-113272309-B | Tricyclic inhibitors of hepatitis b virus | 圣拉斐尔医院有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | ANTIOS THERAPEUTICS INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11504382-B2 | Tricyclic inhibitors of Hepatitis B virus | Antios Therapeutics, Inc. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2022-04-14 | — | — | US | disclosed |
| CN-113272309-A | Tricyclic inhibitors of hepatitis B virus | 圣拉斐尔医院有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3608326-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11504382-B2 | Tricyclic inhibitors of Hepatitis B virus | HAVCR2, NR1H4, HCCS | NR1H2 9/4885HSD17B10 210/4885SMN1; SMN2 4878/4885 |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, NR1H4, HCCS | NR1H2 9/4885HSD17B10 210/4885SMN1; SMN2 4878/4885 |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, HDGF, SLC10A1 | NR1H2 17/4885HSD17B10 729/4885SMN1; SMN2 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.